Tekla Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Tekla Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.17M	Sell	150,418 -44,607	-23%	-$376K	0.05%	127
2023 Q1	$1.3M	Hold	195,025	–	–	0.05%	132
2022 Q4	$1.74M	Hold	195,025	–	–	0.07%	118
2022 Q3	$1.92M	Buy	195,025 +134,475	+222%	+$1.36M	0.08%	114
2022 Q2	$482K	Hold	60,550	–	–	0.02%	153
2022 Q1	$587K	Hold	60,550	–	–	0.02%	156
2021 Q4	$925K	Buy	+60,550	New	+$1.09M	0.03%	147

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tekla Capital Management's EWTX Position: Q2 2023 in Review

Tekla Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 23% in Q2 2023, selling an estimated $376K and leaving 150,418 shares worth $1.17M. The position accounts for 0.05% of the portfolio, ranked #127.

Tekla Capital Management first reported a position in EWTX in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.92M in Q3 2022. 95 funds tracked by Wall St. Rank hold EWTX as of Q2 2023.

Tekla Capital Management held 150,418 shares of Edgewise Therapeutics worth $1.17M as of Q2 2023.
Tekla Capital Management sold 44,607 Edgewise Therapeutics shares in Q2 2023, an estimated $376K.
Edgewise Therapeutics made up 0.05% of Tekla Capital Management's portfolio in Q2 2023, its #127 holding.
Tekla Capital Management first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 7 quarters since.
Tekla Capital Management's Edgewise Therapeutics position peaked at $1.92M in Q3 2022.
95 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.